Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28119259 | 0.89 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL12786341 | 0.89 | NPC1 (0.60) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL775333 | 0.87 | NPC1 (0.61) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6986767 | 0.86 | LMNA (0.47) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL196861 | 0.82 | GCGR (0.67) | PDGFRBPDGFRARAB9ASMN1; SMN2MAPT | |
| SCHEMBL9098509 | 0.80 | NPC1 (0.80) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9099501 | 0.80 | NPC1 (0.80) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9098395 | 0.80 | NPC1 (0.80) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27550563 | 0.80 | NPC1 (0.51) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14964814 | 0.79 | SMN1; SMN2 (0.78) | PDGFRBPDGFRARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| EP-1282614-A1 | HYDROXAMIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| WO-2001087870-A1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | PDGFRB 1912/4885PDGFRA 1622/4885RAB9A 3312/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | PDGFRB 1912/4885PDGFRA 1622/4885RAB9A 3312/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | PDGFRB 1912/4885PDGFRA 1622/4885RAB9A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.